Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
David McConkey PhD

David J. McConkey PhD

Director, Johns Hopkins Greenberg Bladder Cancer Institute; Professor, Brady Urological Institute, Johns Hopkins, Baltimore, Maryland

David J. McConkey, PhD, is a Professor in the Departments of Urology and Cancer Biology and Director of Urological Research at U.T. M.D. Anderson Cancer Center. He also serves as co-Principal Investigator of the MD Anderson SPORE in Bladder Cancer, Chair for Translational Medicine for the Genitourinary Cancers Committee of the Southwest Oncology Group (SWOG), and a member of the Bladder Cancer Advocacy Network’s (BCAN’s) Bladder Cancer Genomics Consortium (BCGC) Advisory Committee.  His research interests are focused on using genomics to identify the molecular mechanisms underlying bladder cancer heterogeneity and to use this information to transform the clinical management of patients with bladder cancer.

Recent Contributions to PracticeUpdate:

  1. Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
  2. Elucidating Prostate Cancer Behavior During Treatment via Low-Pass Whole-Genome Sequencing of ctDNA
  3. Molecular Correlates of Cisplatin-Based Chemotherapy Response in MIBC
  4. Cancer Susceptibility Mutations in Patients With Urothelial Malignancies
  5. Early Detection and Monitoring of Urothelial Bladder Carcinoma by Ultra-Deep Sequencing of ctDNA
  6. Genomic Differences Between "Primary" and "Secondary" Muscle-Invasive Bladder Cancer and Neoadjuvant Chemotherapy Outcomes
  7. Liquid Biopsies for Bladder Cancer Surveillance: Success Is in Sight
  8. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer
  9. Urine DNA Testing for Detecting Bladder Cancer in Patients With Gross Hematuria
  10. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer

Recently Updated